Genicular Nerve Block in Rheuamtoid Arthritis

Genicular Nerve Block in Rheumatoid Arthritis: a Prospective Randomized Clinical Trial

N=64 RA patients either early or established disease diagnosed after ACR/EULAR criteria 2010 with unilateral persistent knee arthritis. They were randomly assigned into two groups; group 1 received genicular nerve block, group 2 intra-articular triamcinolone. Both groups were examined by SOLAR scoring system, Visual analogue scale (VAS) and Lysholm score at 0, 2 and 12 weeks. A semi-quantitative score was used to assess tenderness and swelling at the same intervals.

Inclusion Criteria:

• RA patients
• Age > 18
• unilateral persistent knee arthritis

Exclusion Criteria:

• Participants with severe knee osteoarthritis
• peripheral neuropathy
• psoriatic arthritis
• skin infection
• or those who have allergy for Bupivacaine